Understanding personal circadian rhythms may hold the key to preventing metabolic disease, as emerging evidence suggests that when your heart beats fastest during the day carries significant health implications. This connection between internal biological timing and disease risk represents a potential paradigm shift from viewing chronotype as merely a lifestyle preference to recognizing it as a measurable health biomarker.
Analyzing wearable device data from nearly 16,000 participants in the All of Us Research Program, investigators identified heart rate phase (HRP) as a quantitative measure of circadian timing. Participants averaged an HRP of 9.48 hours, meaning peak heart rate occurred mid-morning for most individuals. Those with later heart rate peaks—indicating evening chronotypes—showed increased risks for addiction, mood disorders, sleep disturbances, and metabolic conditions. Most notably, each hour delay in heart rate phase corresponded to a 9% increase in type 2 diabetes risk. Genetic analysis revealed that individuals carrying the rs1144566(T) variant, associated with morning preference, had earlier heart rate peaks and 31% lower diabetes risk.
This research bridges a critical gap between laboratory circadian studies and real-world health outcomes. Previous chronotype research relied heavily on questionnaires about sleep preferences, but wearable-derived heart rate phase provides objective, continuous measurement of biological timing. The causal relationship suggested by Mendelian randomization analysis indicates that circadian timing itself—not merely lifestyle factors—may directly influence metabolic health. However, the findings require validation across diverse populations and longer follow-up periods. If confirmed, heart rate phase monitoring could enable personalized interventions targeting circadian optimization for diabetes prevention, transforming how we approach metabolic disease risk assessment.